In Vivo CAR T-Cell Therapy KLN-1010 Achieves 100% MRD Negativity in Multiple Myeloma Phase 1 Trial, Presented at ASCO/EHA 2026

International Myeloma Foundation USA

Overview

At the 2026 ASCO and EHA meetings, groundbreaking results for KLN-1010, an in vivo CAR T-cell therapy eliminating the need for ex vivo T-cell harvest, were highlighted. The clinical trial in multiple myeloma reported that all patients achieved minimal residual disease (MRD) negativity within one month post-treatment. This novel approach has the potential to drastically reduce manufacturing complexity and costs associated with conventional CAR T therapies, significantly enhancing global access to CAR T-cell treatments and potentially transforming the future of cancer care.

In Depth

Key Findings

At the 2026 ASCO and EHA conferences, early clinical trial results for KLN-1010, an innovative in vivo CAR T-cell therapy that bypasses the need for patient T-cell harvesting, garnered significant attention. This treatment for multiple myeloma patients demonstrated exceptionally promising outcomes, with all patients achieving minimal residual disease (MRD) negativity within just one month post-treatment. This breakthrough has the potential to resolve major manufacturing bottlenecks in CAR T-cell therapy and dramatically improve global access to these life-saving treatments.

Technical & Clinical Details

KLN-1010 employs a revolutionary approach by generating CAR T cells directly within the patient’s body. Traditional CAR T-cell therapy requires a time-consuming and costly ex vivo manufacturing process involving T-cell collection from the patient, genetic modification, expansion, and reinfusion. In contrast, KLN-1010 involves direct administration of specialized viral vectors or nanoparticles into the patient, which then reprogram endogenous T cells into CAR T cells in situ. This eliminates the need for apheresis, ex vivo culturing, and infusion procedures, drastically shortening the treatment timeline and reducing manufacturing costs. The reported clinical trial involved advanced multiple myeloma patients treated with KLN-1010.

• Response Rate: While detailed objective response rates (ORR) were not explicitly published in the abstract, the achievement of “100% MRD negativity in all patients” indicates a profound level of response. MRD negativity refers to the absence of detectable disease at a molecular level post-treatment, signifying a very strong therapeutic effect.
• Safety Profile: The abstract did not provide specific numbers for severe cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). However, an in vivo approach might present a different safety profile compared to ex vivo manufactured CAR T therapies, warranting further detailed investigation in larger trials.
• Patient Number: As an early-phase clinical trial, it is presumed that a limited number of patients were enrolled.

This approach is particularly beneficial for patients with compromised T-cell quality or expansion capabilities, or those requiring rapid therapeutic intervention.

Background & Context

Despite their remarkable efficacy in certain hematological malignancies, the complex manufacturing processes of CAR T-cell therapies pose significant barriers to widespread adoption. Production requires highly specialized expertise and facilities, limiting availability to a select few centers. Moreover, autologous CAR T therapy, which uses patient-derived T cells, necessitates individualized manufacturing for each patient, incurring high costs and long waiting periods. In vivo CAR T-cell therapy is heralded as a next-generation cell therapy with the potential to simultaneously address these challenges. It is receiving substantial attention from researchers and pharmaceutical companies worldwide, as it could “democratize” CAR T-cell therapy, making it accessible in more countries and regions.

Strategic Significance & Outlook

The groundbreaking achievement of 100% MRD negativity with KLN-1010’s in vivo CAR T-cell therapy in an early clinical trial will profoundly impact multiple myeloma treatment and, by extension, oncology as a whole. Future research must involve larger clinical trials to thoroughly evaluate its long-term safety, efficacy, and comparative advantages over existing CAR T-cell therapies. If this approach proves broadly successful, the dramatic reduction in CAR T-cell manufacturing costs and time could establish it as an accessible standard of care for patients globally. Its potential application to solid tumors also positions this technology as a critical factor in shaping the future of cancer immunotherapy.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime